Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$-- Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$0 Mln
ROE
-3.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
8.4
Industry P/E
--
EV/EBITDA
-0.7
Div. Yield
0 %
Debt to Equity
-0.6
Book Value
$--
EPS
$-0.1
Face value
--
Shares outstanding
113,356,000
CFO
$-514.41 Mln
EBITDA
$-441.71 Mln
Net Profit
$-653.95 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Evofem Biosciences (EVFM)
| -- | -- | -- | -- | -96.0 | -93.8 | -79.4 |
|
BSE Sensex
| 5.2 | 7.3 | 8.4 | 12.8 | 16.0 | 21.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Evofem Biosciences (EVFM)
| -84.4 | -60.9 | 47.3 | -64.0 | 74.1 | -19.4 | -81.4 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Evofem Biosciences (EVFM)
|
0.0 | 1.0 | 19.4 | -8.9 | -39.4 | 12.9 | -- | 8.4 |
| 19.7 | 4,746.1 | 426.5 | 197.7 | 32.7 | 81.6 | 23.7 | 12.7 | |
| 107.5 | 5,294.4 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 99.5 | |
| 59.3 | 11,257.3 | 2,937.8 | 523.9 | 23.2 | 9.3 | 21.7 | 2.0 | |
| 33.8 | 6,391.4 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 75.1 | 7,961.9 | 685.5 | 132.9 | 15.6 | 20.1 | 65.3 | 11.7 | |
| 12.9 | 6,426.6 | 4,427.0 | 373.0 | -0.7 | 5.8 | 17.2 | 1.0 | |
| 63.3 | 11,778.7 | 4,413.2 | 21.3 | 7.2 | 0.6 | 304.3 | 3.1 | |
| 89.1 | 4,402.4 | 1,137.8 | 214.6 | 29.2 | 12.3 | 20.8 | 2.3 | |
| 8.8 | 9,882.4 | 14,590.8 | -1,264.6 | -5.6 | -6.6 | -- | 0.6 |
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a vaginal gel for the prevention... of pregnancy; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California. Read more
Interim Chair, President & CEO
Ms. Saundra Pelletier
Interim Chair, President & CEO
Ms. Saundra Pelletier
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Evofem Biosciences Inc (EVFM) stood at $ 24 Mln as on 31-Dec-24
The share price of Evofem Biosciences Inc (EVFM) is $0.01 (NASDAQ) as of 16-May-2025 13:33 EDT. Evofem Biosciences Inc (EVFM) has given a return of -95.99% in the last 3 years.
Evofem Biosciences Inc (EVFM) has a market capitalisation of $ 1 Mln as on 16-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Evofem Biosciences Inc (EVFM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Evofem Biosciences Inc (EVFM) and enter the required number of quantities and click on buy to purchase the shares of Evofem Biosciences Inc (EVFM).
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a vaginal gel for the prevention of pregnancy; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
The CEO & director of Ms. Saundra Pelletier. is Evofem Biosciences Inc (EVFM), and CFO & Sr. VP is Ms. Saundra Pelletier.
There is no promoter pledging in Evofem Biosciences Inc (EVFM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,178
|
|
|
1,126
|
|
|
988
|
|
|
751
|
|
|
647
|
|
|
639
|
|
|
510
|
|
|
475
|
|
|
422
|
| Evofem Biosciences Inc. (EVFM) | Ratios |
|---|---|
|
Return on equity(%)
|
12.86
|
|
Operating margin(%)
|
-39.64
|
|
Net Margin(%)
|
-45.76
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Evofem Biosciences Inc (EVFM) was $0 Mln.
$-0.06
(
